Butyrolactone 3

Butyrolactone 3 (MB-3) is a specifical small-molecule inhibitor of the histone acetyltransferase Gcn5 (IC50=100 μM), which has a high affinity to the Gcn5 enzyme comparable to that of its natural substrate, histone H3. Butyrolactone 3 shows weak inhibitory on CBP (IC50=0.5 mM) . Butyrolactone 3 can be used in studies of cancer, metabolic, autoimmune and neurological diseases[1][2][3].

Product Specifications

CAS Number

[778649-18-6]

Product Name Alternative

MB-3

UNSPSC

12352005

Hazard Statement

H319

Target

Histone Acetyltransferase

Type

Reference compound

Related Pathways

Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer; Metabolic Disease; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/butyrolactone-3.html

Purity

99.58

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C([C@@H](C1=C)[C@@H](CCC)OC1=O)O

Molecular Formula

C9H12O4

Molecular Weight

184.19

Precautions

H319

References & Citations

[1]Biel M, et al. Design, synthesis, and biological evaluation of a small-molecule inhibitor of the histone acetyltransferase Gcn5.Angew Chem Int Ed Engl. 2004 Jul 26;43 (30) :3974-6|[2]Haque ME, et al. The GCN5: its biological functions and therapeutic potentials. Clin Sci (Lond) . 2021 Jan 15;135 (1) :231-257. |[3]Holmlund T, et al. GCN5 acetylates and regulates the stability of the oncoprotein E2A-PBX1 in acute lymphoblastic leukemia. Leukemia. 2013 Mar;27 (3) :578-85.